BELINDA HOLDEN: Open Payments
NPI 1033581152 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,449 in 67 payments from 11 companies in 2025. Trend: 2023 $1,414 · 2024 $1,804 · 2025 $1,449
Food & beverage: $1,449
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $393 |
| Axsome Therapeutics, Inc. | 8 | $259 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $192 |
| Supernus Pharmaceuticals, Inc. | 7 | $131 |
| Janssen Pharmaceuticals, Inc | 5 | $87 |
| E.R. Squibb & Sons, L.L.C. | 4 | $86 |
| Corium, LLC | 4 | $79 |
| Alkermes, Inc. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
Products named: VRAYLAR, Auvelity, CAPLYTA, Qelbree, SPRAVATO, COBENFY, Azstarys, LYBALVI.
Industry payments across MS — which companies pay providers there.
